A CDMO perspective toward the implementation of continuous bioprocessing stand- alone and integrated offerings
October 6-10, 2019
The challenge involved in integrating unit operations for continuous bioprocessing is a significant impediment to implementation of the technology in the industry. The benefit of continuous bioprocessing can be better understood when the components of the technology are analyzed under multiple factors including modalities, protein quality attributes and stability, specific productivity and overall cost-benefit of implementation and operation of the technology. Contract Development and Manufacturing Organizations (CDMO) need to provide a portfolio of offerings that cover the needs of diverse groups and process needs. For example, processes with lower productivity and unstable molecules can benefit from a perfusion system while more stable molecules with high productivity may need to focus on the benefits of a continuous capture to address a potential bottleneck on the downstream.
Please click Additional Files below to see the full abstract.
Claudia Berdugo-Davis, Kevin Humbard, Ben Kester, Emily Schirmer, Brian Follstad, Ian Collins, Li Yunsong, Victor Vinci, and William Wessel, "A CDMO perspective toward the implementation of continuous bioprocessing stand- alone and integrated offerings" in "Integrated Continuous Biomanufacturing IV", Veena Warikoo, Roche, USA Alois Jungbauer, BOKU, Austria Jon Coffman, Boehringer Ingelheim, USA Jason Walther, Sanofi, USA Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/biomanufact_iv/5